An update from Adaptimmune Therapeutics ( (ADAP) ) is now available.
Adaptimmune Therapeutics provided a business update for Q4 and the full year 2024, highlighting the successful launch momentum of its sarcoma franchise product, Tecelra, with 10 patients apheresed in Q1 2025 and 3 in 2024. The company achieved all manufacturing and supply goals and is on track to expand its network of Authorized Treatment Centers by the end of 2025. Additionally, Adaptimmune completed a corporate restructure in February 2025, implementing cost reductions for its PRAME and CD70 programs, and is evaluating strategic options to maximize shareholder value. The company aims for profitability by 2027 while addressing concerns about its ability to continue as a going concern.
More about Adaptimmune Therapeutics
Adaptimmune Therapeutics is an integrated cell therapy company focused on redefining cancer treatment. Utilizing its engineered T cell receptor (TCR) platform, the company aims to develop personalized medicines targeting solid tumor cancers to enhance the patient treatment experience.
YTD Price Performance: -27.58%
Average Trading Volume: 1,329,368
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $116.5M
Find detailed analytics on ADAP stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com